Todd Broome, MD
Nephrology · Huntsville, ALNPI 1588636757
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,300 of the $7,110 with a category attached, or 88.6%. It is spread thinly across 29 manufacturers, the largest accounting for just 17.4% — the pattern of someone who eats at a lot of different presentations.
Across 355 payments — averaging $20.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bard Peripheral Vascular, Inc.$1K
- AstraZeneca$675
- Vifor Pharma, Inc.$667
- Otsuka America Pharmaceutical, Inc.$493
- OPKO Pharmaceuticals, LLC$485
- Novartis$479
- plus $3K from 23 others
What the payments were for
- Travel & lodging$77011%
- Food & beverage$6,30089%
- Education$401%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bard Peripheral Vascular, Inc. | 13 | $1,237 |
| AstraZeneca(2 entities) | 44 | $675 |
| Vifor Pharma, Inc. | 36 | $667 |
| Otsuka America Pharmaceutical, Inc. | 27 | $493 |
| OPKO Pharmaceuticals, LLC | 49 | $485 |
| Novartis | 18 | $479 |
| GSK | 29 | $456 |
| Bayer | 17 | $369 |
| Travere Therapeutics, Inc. | 28 | $354 |
| Boehringer Ingelheim | 13 | $284 |
| Amgen(2 entities) | 15 | $273 |
| Fresenius USA Marketing, Inc. | 10 | $190 |
| Calliditas Therapeutics US Inc. | 8 | $158 |
| Aurinia Pharma U.S., Inc. | 6 | $148 |
| Novo Nordisk | 7 | $134 |
| Ardelyx, Inc. | 5 | $116 |
| Lilly USA, LLC | 5 | $99 |
| Daiichi Sankyo Inc. | 5 | $89 |
| Ultragenyx Pharmaceutical Inc. | 3 | $74 |
| Medtronic | 3 | $74 |
| Cycle Pharmaceuticals Inc | 3 | $60 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $42 |
| Akebia Therapeutics Inc | 2 | $41 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $33 |
| Mallinckrodt Hospital Products Inc. | 1 | $18 |
| Cormedix Inc. | 1 | $18 |
| Genentech USA, Inc. | 1 | $16 |
| Kyowa Kirin, Inc. | 1 | $15 |
| Lemaitre Vascular, Inc. | 1 | $14 |
How this compares
$7,110 in reported general payments places this provider in the 80th percentile of 164 nephrology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 377 | $337,887 |
| LupkynisVoclosporin | 14 | $136,595 |
| SamscaTolvaptan | 12 | $73,033 |
| RayaldeeCalcifediol | 47 | $66,400 |
| JardianceEmpagliflozin | 52 | $57,946 |
| VelphoroSucroferric Oxyhydroxide | 20 | $54,010 |
| LokelmaSodium Zirconium Cyclosilicate | 37 | $31,970 |
| Sevelamer Carbonate | 91 | $24,063 |
| Lanthanum Carbonate | 18 | $17,497 |
| DapagliflozinDapagliflozin Propanediol | 17 | $14,481 |
| VeltassaPatiromer Calcium Sorbitex | 16 | $11,481 |
| Nifedipine ErNifedipine | 129 | $3,564 |
| Potassium Citrate ErPotassium Citrate | 16 | $2,973 |
| Labetalol Hcl | 42 | $2,569 |
| Cinacalcet Hcl | 26 | $2,465 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $675 | $369,857414 claims |
| Aurinia Pharma U.S., Inc.Lupkynis | $148 | $136,59514 claims |
| Otsuka Pharmaceutical Development & Commercialization, Inc.Samsca | $33 | $73,03312 claims |
| OPKO Pharmaceuticals, LLCRayaldee | $485 | $66,40047 claims |
| Boehringer IngelheimJardiance | $284 | $57,94652 claims |
| Fresenius USA Marketing, Inc.Velphoro | $190 | $54,01020 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 164 nephrology providers in Alabama.
Other nephrology in Huntsville
- Michael QuadriniHuntsville$323K
- James SmelserHuntsville$20K
- Carlo CastilloHuntsville$7K
- Heather HaleyHuntsville$6K
- Saad RahmanHuntsville$6K
- Roger CoomerHuntsville$6K
- David BainsHuntsville$5K
- Dana RizkBirmingham$196K
- Sumeet MunjalMontgomery$191K
- Eric WallaceBirmingham$172K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.